ACIU AC Immune SA Total Debt to Capital

AC Immune (ACIU) is a high-authority Swiss brand specializing in the development of Alzheimer's treatments. The business's financial success relies on collaborations with major corporations to commercialize dementia tests and vaccines. Laboratory processes are accelerating through the implementation of automated biomaterial screening systems. The total debt-to-equity ratio stands at 0.12, which is clearly demonstrated by this price action chart.

An analysis of the capital structure allows for the separation of AC Immune's fundamental stability from short-term market volatility. This metric compares total liabilities with net assets to determine the business's degree of dependence on borrowed funds. The debt-to-equity ratio trend reflects financial leverage risk. For a biopharmaceutical company developing immunotherapy for Alzheimer's disease, this is a critical marker of solvency. A low debt level confirms the company's ability to fund long-term scientific research.